Satoris Launches Protein-Based Parkinson's Study with Grant from Michael J. Fox Foundation

Satoris will use a panel of 500 signaling proteins and antibody-based quantitative nitrocellulose filter membrane array technology to search for candidate biomarkers for the disease. In May, it launched its first commercial products, protein panels for Alzheimer's disease and dementia.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.